Stockreport

Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights

Biodesix, Inc.  (BDSX) 
PDF Persistent, high double-digit growth in Lung Diagnostic test volume - growing 65% in FY2023 versus FY2022 - and the sixth consecutive quarter with greater than 50% year- [Read more]